Related Experiment Video
Updated: Jul 28, 2026
07:41
Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
Published on: March 17, 2022
Cadmium: hypertension induction and lead mobilization
Journal of the National Medical Association
|December 1, 1979
Summary
Cadmium exposure in rats significantly increased systolic blood pressure and altered lead metabolism. This suggests cadmium may contribute to hypertension by mobilizing lead in the body.
Area of Science:
- Environmental toxicology
- Trace metal metabolism
- Cardiovascular physiology
Background:
- Cadmium is an environmental toxicant with no known essential function.
- Cadmium exposure is suspected to contribute to pathological conditions like hypertension.
- Cadmium may interfere with the metabolism of other essential trace metals, such as lead and zinc.
Purpose of the Study:
- To investigate the association between cadmium exposure and hypertension.
- To examine the effect of cadmium on lead metabolism in rats.
Main Methods:
- Female Sprague-Dawley rats were administered cadmium nitrate.
- Systolic blood pressure and body weight were monitored weekly.
- Cadmium and lead levels in kidney and liver tissues were quantified using atomic absorption spectrophotometry.
Main Results:
- Cadmium-treated rats exhibited significantly higher systolic pressures (155 ± 10 mmHg) compared to controls (96 ± 5 mmHg) after 36 weeks.
- Elevated cadmium levels were detected in the liver and kidneys of treated rats.
- Increased urinary excretion of delta-aminolevulinic acid in cadmium-exposed rats indicated induced lead mobilization.
Conclusions:
- Cadmium exposure leads to increased blood pressure in rats.
- Cadmium administration promotes the release of lead from tissues, suggesting a role in lead toxicity.
- These findings highlight cadmium's potential to exacerbate lead-induced pathologies, including hypertension.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:28Cardiac Catheterization I: Pre-Procedure Overview
Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...